Brain α7 nicotinic acetylcholine receptors in MPTP-lesioned monkeys and parkinsonian patients - Morissette, Marc; Morin, Nicolas; Grégoire, Laurent; Rajput, Alex; Rajput, Ali H.; Di Paolo, Thérèse (Biochemical pharmacology, 2016)
Keywords: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine - administration & dosage; Aged; Aged, 80 and over; alpha7 Nicotinic Acetylcholine Receptor - agonists; alpha7 Nicotinic Acetylcholine Receptor - genetics; alpha7 Nicotinic Acetylcholine Receptor - metabolism; Animals; Antiparkinson Agents - adverse effects; Bungarotoxins - metabolism; Case-Control Studies; Caudate Nucleus - drug effects; Caudate Nucleus - metabolism; Caudate Nucleus - pathology; Corpus Striatum - drug effects; Corpus Striatum - metabolism; Corpus Striatum - pathology; Dyskinesia, Drug-Induced - metabolism; Dyskinesia, Drug-Induced - physiopathology; Dyskinesia, Drug-Induced - prevention & control; Excitatory Amino Acid Antagonists - pharmacology; Female; Gene Expression; Human; Humans; Iodine Radioisotopes; L-DOPA-induced dyskinesia; Levodopa - adverse effects; Macaca fascicularis; Male; MPTP-lesioned monkey; Organ Specificity; Ovariectomy; Parkinson Disease - drug therapy; Parkinson Disease - metabolism; Parkinson Disease - pathology; Parkinson Disease, Secondary - chemically induced; Parkinson Disease, Secondary - drug therapy; Parkinson Disease, Secondary - metabolism; Parkinson Disease, Secondary - pathology; Parkinson’s disease; Putamen - drug effects; Putamen - metabolism; Putamen - pathology; Pyridines - pharmacology; Signal Transduction; α7 nicotinic acetylcholine receptor; KRH; Hepes; DL; DM; MPTP-lesioned monkey; BSA; L-DOPA; GPe; L-DOPA-induced dyskinesia; Human; GPi; LID; GP; MPEP; nACh; AIMs; mGlu; PD; VL; VM; MPTP; NAM; DA; Parkinson’s disease; α7 nicotinic acetylcholine receptor